All patients having the ultrasound to their prostates are still alive five years later This is the same survival rate as those undergoing surgery or radiotherapy Yet ultrasound treatment causes 2% lower urinary-incontinence rates It also reduces the risk of suffering erectile dysfunction by 15% Prostate cancer affects one in every eight men in the UK and 11% in...
Tag: <span>Prostate cancer</span>
Post
Lethal prostate cancer treatment may benefit from combination immunotherapy
JOHNS HOPKINS MEDICINE Researchers at the Johns Hopkins Kimmel Cancer Center and the Bloomberg~Kimmel Institute for Cancer Immunotherapy (BKI) released a study investigating the use of combination checkpoint immunotherapy in the treatment of a lethal form of advanced prostate cancer. The study suggested a genetic subset of prostate cancer may benefit from this form of immunotherapy....
Post
Researchers pinpoint new subtype of prostate cancer
Tumors with alterations in the CDK12 gene were more responsive to immunotherapy, suggesting precision medicine approach MICHIGAN MEDICINE – UNIVERSITY OF MICHIGAN IMAGE: DEPICTION OF THE MOLECULAR PROCESSES INVOLVED IN A NEW SUBTYPE OF METASTATIC PROSTATE CANCER CHARACTERIZED BY LOSS OF THE GENE CDK12. CREDIT: ALEXANDER TOKAREV, ELLA MARU STUDIO ANN ARBOR, Michigan — Researchers led...
Post
Researchers identify new gene changes that point to elevated prostate cancer risk
Findings may help identify men who need early, regular screening CASE WESTERN RESERVE UNIVERSITY As the result of a six-year long research process, Fredrick R. Schumacher, PhD, a cancer epidemiology researcher at Case Western Reserve University School of Medicine, and an international team of more than 100 colleagues have identified 63 new genetic variations that could indicate...
Post
Prostate cancer survivors more susceptible to chronic diseases
Prostate cancer survivors taking androgen deprivation therapy (ADT), a treatment commonly used to block the release of male hormones, are at a higher risk of developing chronic diseases, according to new research published this week. In a study analysing the pharmaceutical records of about 3,700 prostate cancer survivors from 2003 to 2014, University of South Australia (UniSA) researchers examined the development...
Post
Experts have new advice on prostate cancer screening. Here’s why they put it back on the table
In a shift that puts early detection of prostate cancer back on the agenda of middle-aged men and their doctors, a federal panel of experts is recommending that men ages 55 to 69 weigh the potential harms and benefits of prostate cancer screening and judge whether getting tested feels right to them. A recommendation issued Tuesday by...
Post
Study reveals a way to make prostate cancer cells run out of energy and die
Scientists at Cold Spring Harbor Laboratory (CSHL) have discovered that cells lacking the tumor-suppressor protein PTEN—a feature of many cancers— are particularly vulnerable to drugs that impair their energy-producing mitochondria. Such drugs induce them to literally eat themselves to death, the research shows. Unlike normal cells, cells without PTEN seem driven to preserve their mitochondria at...
Post
Exome Meta-Analysis Uncovers Copious Prostate Cancer Drivers
NEW YORK (GenomeWeb) – A new meta-analysis of prostate cancer exomes has identified dozens of potential driver genes, including genes mutated in just a fraction of the cancer cases considered. In an effort to expand on prior genomic studies of prostate cancer, researchers from the US and UK used the same analytical strategy to assess...
Post
Taking a standard prostate cancer drug with food boosts impact, lowers cost
By taking a high-cost drug with a low-fat meal—instead of on an empty stomach, as prescribed—prostate cancer patients could decrease their daily dose, prevent digestive issues and cut costs by 75 percent, according to a new study in the March 28, 2018, issue of the Journal of Clinical Oncology (JCO). Abiraterone acetate, marketed as Zytiga, is...
Post
New insights into prostate cancer treatment and screening
In four recent publications in the Journal of Clinical Oncology (JCO), Maha Hussain, MD, deputy director of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, detailed new findings related to therapies for advanced prostate cancer, and called for a balanced approach to early detection of the disease. “This represents a good portion of...